|WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) this week for the Novavax COVID-19 two-dose injection for adults 18 years and over.
Novavax is a subunit protein “vaccine” that places parts of the COVID-19 spike protein directly in the body. However, Novavax and the FDA panel previously stated that two doses of the Novavax shot will not be enough to “protect” people from the virus and repeated boosting will be necessary. The shot was developed over two years ago, but there is no trial data on the Delta and Omicron variants.
Despite erroneous claims that Novavax’s COVID-19 injection (NVX-CoV2373) does not have any connection to abortion-derived cell lines, evidence from Novavax’s own published study shows otherwise. While Novavax claims that no human fetal-derived cell lines or tissue, including HEK293 cells, were used in the development, manufacture, or production of the Novavax COVID-19 shots, it is not true that there is no association with abortion because an aborted fetal cell line was used in the testing phase of Novavax. Novavax’s published study, “Structural Analysis of Full-Length SARS-CoV-2 Spike Protein From an Advanced Vaccine Candidate,” shows that the HEK293 aborted fetal cell line was used in the testing phase. The HEK293 cell line was originally harvested from the kidney of an aborted baby girl in 1973.
|In a letter obtained by the Charlotte Lozier Institute, Novavax admits that HEK293 cells were indeed used as part of the testing phase for NVX-CoV2373:
“Testing was conducted to compare the structural integrity of the SARS-CoV-2 spike protein produced in the Sf9 insect cells versus the spike protein produced in the mammalian human embryonic kidney HEK 293F cells. The comparison determined the Sf9 cell technology produced spike proteins were comparable in structural integrity as the spike proteins produced in the HEK 293F cell.”
The Novavax shot, like mRNA COVID injections, has also demonstrated increased risk for heart inflammation. Several cases of myocarditis and pericarditis were observed in the trial participants within two weeks of injection. Even though Novavax has denied the connection between its shot and reported cases of heart inflammation, the briefing document for the Vaccines and Related Biological Products Advisory Committee meeting on June 7, revealed severe local adverse events occurred in 1.2 to 7.2 percent of Novavax recipients, and systemic adverse events occurred in 2.4 percent to 12.1 percent of Novavax recipients.
Yesterday, the European Medicines Agency updated the label for the Novavax injection to include the risk of severe allergic reactions to people with a history of reactions to any components of the shot.
Similar to Moderna and BioNTech, Novavax has never successfully brought a product to market in its 33-year history. The company has zero track record of success, safety, and/or efficacious products.
Liberty Counsel Founder and Chairman Mat Staver said, “Novavax used aborted fetal cell lines in the testing phase. And just like the other COVID shots, it is already known that Novavax increases the risk of myocarditis and other adverse reactions. But the FDA continues to rubber stamp pharmaceutical companies with no history of success so long as the product is associated with COVID-19.” Liberty Counsel is a public law firm and a news partner with the Wyoming News.